Showing results (81-90 of 137) with videos related to

Sort By:
Pageof 14
Frontiers in Oncology|August 29, 2019
<i>BCR-ABL1</i> Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase InhibitorsMaria Stella Pennisi, Stefania Stella, Silvia Rita Vitale, et al.
International Journal of Molecular Sciences|June 12, 2026
Proteome and miRNAs Expression in Medication-Related Osteonecrosis of the JawAlessandro Allegra, Rossana De Salvo, Antonia Marcianò, et al.
Frontiers in Oncology|February 18, 2022
Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study)Anna Sicuranza, Ilaria Ferrigno, Elisabetta Abruzzese, et al.
Blood|October 14, 2009
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemiaGianantonio Rosti, Francesca Palandri, Fausto Castagnetti, et al.
Leukemia|September 4, 2019
Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapyFabio Efficace, Fabio Stagno, Alessandra Iurlo, et al.
Cancers|April 3, 2021
Targeting Chronic Myeloid Leukemia Stem/Progenitor Cells Using Venetoclax-Loaded ImmunoliposomeMohammad Houshmand, Francesca Garello, Rachele Stefania, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2017
High <i>BCR-ABL/GUS</i> Levels at Diagnosis of Chronic Phase CML Are Associated with Unfavorable Responses to Standard-Dose ImatinibPaolo Vigneri, Fabio Stagno, Stefania Stella, et al.
Leukemia Research|June 28, 2011
Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinibRoberto Latagliata, Massimo Breccia, Fausto Castagnetti, et al.
Cancer Medicine|April 6, 2019
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuationSimona Bernardi, Michele Malagola, Camilla Zanaglio, et al.
British Journal of Haematology|July 3, 2026
Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experienceAndrea Duminuco, Dario Leotta, Alessandro Allegra, et al.
Pageof 14